Tag: pan-DAC inhibitors

Entinostat Doesn’t Overcome Endocrine Resistance in Breast Cancer

The histone deacetylase (HDAC) inhibitor entinostat failed to overcome resistance to endocrine therapy in hormone receptor–positive, HER2-negative, advanced breast cancer in a phase 3 trial....